Oncology

FDA issues complete response letter to Replimune’s RP1 for melanoma

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application (BLA) concerning the RP1 therapy in combination with nivolumab for advanced melanoma.

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC).

PsiQuantum and National Cancer Center Japan partner on quantum computing

PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing within drug discovery and oncology.

Junshi receives China’s NMPA acceptance for toripalimab injection

Junshi Biosciences has received acceptance from China’s National Medical Products Administration (NMPA) for toripalimab subcutaneous injection (JS001sc) new drug applications (NDAs) covering 12 indications for cancer treatment.

Evogene and QUT partner on AI-based cancer therapies

Evogene has partnered with Queensland University of Technology (QUT) in Australia to progress the development of AI-driven small molecule cancer therapeutics.

Innovent and Lilly to advance new oncology and immunology medicines

Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology.

BMS and Microsoft partner for AI-based lung cancer detection

Bristol Myers Squibb (BMS) has entered an agreement with Microsoft to advance AI-driven early lung cancer detection.

Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis

Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer.